Synthetic Minds | Big Pharma Just Bought the AI Before the FDA Saw It

The Synthetic Minds newsletter offers short daily insights to get you thinking. If you enjoy it, please forward. All signals are powered by Futurwise. If you need more insights, subscribe to Futurwise and get 25% off for the first three months!

I have just launched the Intelligence Age Scorecard! It will help you understand how ready your organization is for the Intelligence Age.

Today’s topic: Health & Longevity

Big Pharma Just Bought Tomorrow's Medical AI

This week, three of the world's most powerful players quietly bought the artificial intelligence that is starting to decide who gets which medicine. None of them are doctors. None of them are regulators.

That is the shift hiding under this week's headlines. The AI that whispers in your doctor's ear — who qualifies, who is high-risk, who needs the next test — just got new owners. All in a single week, from the same three places.

Isomorphic Labs just raised $2.1B in Series B funding! What does this mean for AI-driven drug discovery? #IsomorphicLabs #AI #DrugDiscovery | If you're short on time, I've crafted a personalized summary of this article with Futurwise.

Pharma giant Roche paid more than a billion dollars to buy PathAI, one of the leading AI companies in cancer diagnostics. Five days later, Isomorphic Labs, Google's drug-design AI, raised $2.1 billion from Abu Dhabi, Singapore and the British government. The same week, Tempus AI raised another $400 million on Wall Street, with the surplus earmarked for more AI acquisitions.

Three buyers. Three checks. One direction.

In the same seven days, a single gene-editing shot wiped out 87% of attacks in a rare disease, and the company filed for approval. The old way still works — trial, regulator, evidence. It is no longer the only way that decides what reaches you.

That is the AI-in-medicine story. Here is the signal.

Last week I wrote that AI was taking the seat between you and your medicine. This week we learned who is buying that seat. The companies now telling doctors who qualifies and who does not are owned upstream of every regulator and ethics board built to protect you.

A shareholder is not an ethics board. A sovereign wealth fund is not an insurance auditor. The priorities of your future treatment are now set in rooms your governance does not reach.

The question is no longer who governs AI in medicine. It is who owns it — and whose hospital had a seat at the table where that was decided this week.

The Intelligence Age Scorecard

In a single week, three of the most powerful players in the world quietly took ownership of the AI now starting to decide who gets which medicine. WAVE — Watch, Adapt, Verify, Empower — is the question every leadership team owes this week: are you still watching the science, or already verifying which AI vendors will be selling into your organization in 2027? Take the Intelligence Age Scorecard to benchmark your readiness for the next two quarters, and the next five years.

If this newsletter was forwarded to you, you can sign up here.

Thank you.
Mark